Reddit Posts
After 25 years of trading, it has officially retired today.
Day 15: Fullporting my entire account into every trade. MSS (Maison Solutions Inc.) is my trade for today
I REALLY like $MSS. Here are some charts...
Is $MSS Setting Up Like the Recent Penny Runners?
$MSS Watch this one Monday ! Volume spiked Friday . Hammer on Daily ✅
$MSS Mini stock to watch . Bullflag ✅ With all the Squeezes like TRNR , Agae now .
$MSS Mini stock to watch . Bullflag ✅ With all the Squeezes like TRNR , Agae now .
Syndax Pharmaceuticals a promising commercial biotech with multiple approved drugs - Price target $20-56 (M&A possible)
So many big runners called here! This could be next
Penny stock ready to reverse and run hard off bottom
Palantir stock jumps after NATO finalizes purchase of AI military system
$ZJYL shorts crushed a few to keep watching today
Mentions
$MSS did not do $124M in revenue last year. But they did have an $11M loss for the nine months ending Jan 31! https://www.sec.gov/Archives/edgar/data/1892292/000121390026029204/ea0281006-10q_maison.htm#a_003
The volume isn't there for MSS, is anyone still holding
Added more $MSS. Not often do you find a $3M company that did $124M revenue last yr while being profitable. Float is 1.1M too
$MSS great buy here. $2+ target
Joining you degens in MSS based on vibes. Don't fuck me
YMAT, MSS, COSM tomorrow. CXAI this week or next. DBGI right after I sell all of it probably
I’m seeing a lot of people into MSS. I guess I will also join the party
$MSS 1m floater next one that can go 100% to 1000%
starlink mobile doesn’t have a satellite hardware problem it has a architecture problem how much bigger are the phased arrays? The actual d2c apparatus? 20%? 30%? It’s a step up change not a game changer echostar MSS spectrum is gonna help outside, won’t do much in indoor settings. new phones still need to add support and customers with old phones won’t get to use it
SpaceX doesn’t have infinite money, if they want to pour more into this beyond the ~20B Echostar acquisition sure architecturally they need bigger phased arrays… v3 with starship is a decent improvement but won’t be a miracle … hence why they are adding MSS spectrum and hoping for performance gains from handsets as well… but at those frequencies it’s gonna have poor propagation and bad indoor performance which will hurt their TAM… with all this + starship program + xAI + data centers … there’s a reason why Starlink heads got chopped + SpaceX CEO crashed out on MNOs on Friday
Puts without a MSS is nuts. But you do have the fed chair change which historically causes a drawdown. Not to mention smart money wants to kill all these calls
BCG Binah Capital Group and MSS and chill until the weekend.
MSS patience will pay off here. Might be starting. Very clean ticker.
CLRB MSS HOUR good luck !
HOUR and MSS for tomorrow. Position yourselves early boys and girls. Not FA. Good luck whatever you choose 👊
Is MSS a good play the volume jumped up at least 3 times within the past couple hours but it’s still under 1 million so it’s not a lot.
Guys I'm telling you ...if you missed SKK jump into MSS you will see.
I'm in full port on SKK but if can free some capital MSS is a great one to get into right now.
IMO $MSS is the most similar to $JEM, ~1.2m float, already getting attention ww
MSS could be a good play
MSS. CEO is the chairman of SupplyAI. Low float. Any news and this easily moves.
MSS is a potential AI pivot play. The CEO is the chairman of SupplyAI. Reverse splits tomorrow. 1.3m float.
Potential AI pivot play, MSS. The CEO is the chairman of SupplyAI. Look at Maison Solutions (MSS) Twitter account. The account follows SupplyAI and many crypto accounts as they are heavily invested in WorldCoin too.
AMZN is acquiring GSAT to compete with Starlink. GSAT is one of 3 companies who own global MSS spectrum, the other 2 are IRDM and VSAT. Those are the plays now.
There are only 3 companies who own global MSS (Mobile Satellite Services) Spectrum, GSAT, IRDM, and VSAT. He who owns the spectrum, owns the (global) market.
It's the spectrum stupid There are 3 companies who own global MSS spectrum, GSAT, IRDM, and VSAT.
Theres no way some of you retards are buying the narrative. Especially surrounding Chyna doing "nothing". The MSS is 100% giving intelligence to Iranians
It doesn't, even if there were overtures it was from MSS, not the IRGC. IRGC are in charge
That guys an MSS agent for sure
I would just like to say, I really love you guys!! Hahaha. I appreciate the help that this community offers. Obviously you gotta weed out the bots and bullshit, but for a beginning trader, I’ve made 10% on my portfolio in two weeks. Some big winners some big losers but I’ll take 10% with a smile on my face. Thanks for the help chaps! And with that let’s see SLS, MBOT, and MSS bring in some skirlla! 💰
MSS anybody? Making moves premarket. This could really move fast.
I bought MSS Tuesday and seems to be going one way.... down. Is this thing gonna wake up or is it a dead duck?
I bought MSS Tuesday and seems to be going one way.... down. Is this thing gonna wake up or is it a dead duck?
$MSS is gonna run and it’s at a discount, in for 34k shares
MSS RCKT CRML GRCE UCORE If you have any lot of high risk plays together in your PF are they a bit less risky???
$SRXH & $IOBT Maybe $GITS or $MSS
MSS, picked up in pre market. Also added some ONDS.
Rotate my large cap to penny **MSS**
**MSS** need us 2 break .35 It can fly if it breaks
Anyone think it’s too late to buy FFAI, MSS, VNDA?
Added MSS around 0.33 range nfa Not financial advice
MSS todays flip then into SLS
$90-100 EOY? (Copy/pasted since this sub blocks most websites): WHAT'S TO COME IN 2026 FOR AST SPACEMOBILE 2026 Catalysts There are plenty of catalysts the Sp🅰️ceMob are expecting during 2026 and beyond, here's what to keep an eye on Company - Initiation of research coverage by Citi, Goldman Sachs, Jefferies, Morgan Stanley, Stifel etc - Update on process of obtaining L-Band and S-Band spectrum licenses across the globe - Update on Google partnership and implementation plan - Announcement of Apple partnership - Announcement of Sirius XM partnership - Automation of manufacturing processes to enable further scaling Earnings Calls - $50-75M of revenue guided during previous earnings calls - Revenue guidance for 1H 2026 and 2026 - $175M stc prepayment made during Q4 2025, to be reported during Q4 earnings call in early February - Updated manufacturing table showing progress of satellite manufacturing for BlueBirds 14 onwards - Update on EXIM and other non-dilutive funding worth over $500m - Confirmation the company can now produce 6 satellites per month - Update on when the AST5000 ASIC chip will be integrated into the BlueBird satellites - Progress update on the 9 government contracts with Department of Defense (DoD), Space Development Agency (SDA), Defense Innovation Unit (DIU) - Acquisition of new manufacturing space in Midland, TX focused exclusively on Micron production Launch - BB7 launch during Q1 on either SpaceX F9 or Blue Origin New Glenn - BB8 - BB10 transported to Cape Canaveral for launch on SpaceX F9 - BB11 - BB13 transported to Cape Canaveral for launch on SpaceX F9 - Launches of Block 2 satellites in batches of 3-8 satellites every 1-2 months MNOs - Unlocking of $45m prepayment from Verizon upon FCC approval (already signed DA) - Unlocking minimum $20m prepayment from Vodafone - Execution of DAs with 50+ MNOs from around the world including Bell Canada, Etisalat, Orange and Telefonica. These could include prepayments or strategic investments. - FirstNet Investment and Definitive Commercial Agreement - Initial launch of service in conjunction with key strategic MNO partners Government/FCC/Regulatory - Golden Dome awards - Additional government contracts - FCC approval for full US commercial service - Proposal for PNT service accepted by FCC as alternative to GPS - EU allocation of 2GHz MSS spectrum to SatCo (likely 2027)
**Estimated**\- Primary Completion Date 2028 January. "The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. " However-"The main questions this study aims to answer are: 1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, **increase the objective response rate in persons** with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. 2. Is leronlimab safe and well tolerated in these subjects when used in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab." If more than 10%ish of the patients respond the answer to number 1 will be 'yes'. This data will be available long before the safety data final collection date. The actual duration of effects of the trial substances will be-"The time from the first documentation of response, either partial or complete, to the documentation of the objective tumor progression or until death due to any cause. All of this for the current trial protocol which the company is seeking to expande to the inclusion of ICI's. if allowed there will be some revision.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
I have been invested in this company for several years strictly because the science is game changing. This is not hyperbole, that is how some of the Oncologists that have witnessed the results of Leronlimab has described the results they have seen. In the last 2 years Dr. Jacob Lalezari has turned the ship around from past managements deplorable performance. Dr. Lalezari has cleaned up the mess from past managements mistakes and has everything in order to move this drug forward. Looking forward to seeing results from the current MSS-CRC trial
Best Results from CYDY (Leronlimab) Trials – Summary HIV (Combination Therapy & Monotherapy) 1) Achieved primary endpoint in Phase 3 trial for treatment-experienced patients. 2) Some patients on monotherapy maintained viral suppression for years. COVID-19 (Severe/Critical Cases) 1) Phase 3 data showed reduced mortality and faster hospital discharge in critical patients vs. placebo. NASH/MASH (Liver Disease) 1) Phase 2 (open-label): 50% of patients showed ≥80ms reduction in cT1, a key marker of liver disease severity. Preclinical data showed reversal of fibrosis and liver fat reduction. Metastatic Triple-Negative Breast Cancer (mTNBC) 1) In small subgroup, 15/17 patients on ≥525 mg dose showed increased PD-L1 expression (potential synergy with immunotherapy). 2) Some long-term survivors (up to 4 years with no evidence of disease). Metastatic Colorectal Cancer (MSS, CCR5+) 1) FDA cleared Phase 2 trial design combining leronlimab with TAS-102 + bevacizumab. Trial to assess ORR and safety. Promising. Something for the longs to feel hopeful in seeing.
Second rate? They have 70%+ WW MSS in both client and server! How does no one want their product?
**PART 2** Now let’s talk about **Products**. For a long time Intel Products kept the Foundry busy, and Intel’s extreme MSS and margin easily paid for new fabs, whose cost relative to profits was low. What changed was the cost of fabs grew exponentially, Intel stumbled on 10A, and AMD – the main competitor that was always behind on process technology (for contractual reasons) was able to move to TSMC ***and instantly become a node (and almost 2 years) ahead and drive down Intel’s profitability***. This is very apparent when you compare metrics like core counts, power, power/rack, etc. and look at the financials and MSS of both companies. So basically AMD using TSMC can make as-good, in reality even better products than Intel. And in a world that is power conscious, AMD with better power specs is advantaged. What keeps Intel in the game is a strong brand, a strong moat in other business areas (like channel distribution), and quite frankly sometimes customer’s religious belief in Intel. But no matter what your religion, the net/net of all of this is ***Intel MSS and gross margin will continue its downward slide***, AMD’s MSS and gross margin will continue its upward growth until they both meet in the middle. Just look at the last 8 quarterly reports of both companies if you don’t believe it. So Products will have a good business and keep selling Cores and Xeons for the foreseeable future, ***but at a continuing decline in profitability and volume*** (unless they somehow can insert themselves into the AI game). To put some numbers to the challenges above, assuming a net profit margin of 40%, and given 4.3B shares outstanding, to achieve a P/E of 20 (btw TSMC’s is 30) Intel would need a revenue of **$215B**. Note that Intel has never hit $100B. As far as external factors, if there is any type of economic slowdown or recession then demand will drop and affect Intel disproportionally. Keep in mind the inflation due to tariffs hasn’t worked its way into consumer pricing yet. We should start seeing material tariff-induced inflation likely in Q1. On the plus side the Administration’s ***One-for-One chip strategy could be very beneficial to Intel with one caveat***; if Intel’s 18A and/or 14A don’t work or yield well, customers like AAPL simply won’t be able to use them no matter what politicians want. The other positive is that even with a slight downturn it appears AI spending (now est at $3T by 2030) can’t be stopped, and that spending is largely all leading node semis. ***So by financial metrics like P/E you can see INTC is trading on future hope, and the road ahead is an extremely hard one for Foundry and a slowly declining one for Products.*** How high will hype drive the price? Who knows, but at some point when the news wears thin and analysts run the numbers the price will probably peak and start coming back to reflect reality. Personally I think a Foundry customer announcement will jump the stock up again, but unless it’s a huge deal (volume in the millions, multi-year) that might be the last peak before it drops and finds steady-state. IMHO the OP with that cost basis has a lot of money tied up with very little upside and some downside; personally I would probably break that up into several tranches at several price points (say 39 through 45) to both take profits and invest that money into something with more growth potential. The rest of the market is too hot to have a cost basis of $35 and that much money tied up on hype. As for my Call options – they’re all ITM so they’re mostly tracking the stock price at this point, so I’ll wait for that Foundry deal to come and then start unloading, preferably next year (for personal reasons). My personal target is to start unwinding at $40 or higher. But I’ll be looking carefully at the Producer and Consumer inflation reports and other signs that the economy is slowing. My two cents.
Nice position! Since Feb I've been loading up on call options, which were incredible cheap earlier in the year. My investment thesis was pretty simple - a F500, $50B company with 70%+MSS in servers and clients that is one of only three companies that can make the world's most advanced semis and was ***trading at book value***. If that wasn't enough, the current "make-it-in-America" administration commissioned a study into the industry with the only logical conclusion being they are too strategic to fail. Once Trump called for LBT to be fired (his way of inviting him to the White House) it was obvious that they were going to make Intel Foundry successful. Intel doesn't need cash nearly as much as Foundry customers, which is the only thing that will save it. At $35-$40 it's topped out on cash infusion news and trading ***way*** past fundamentals, but news of any **Foundry** business will propel it upward proportionally to the amount of business announced, which will likely be relatively small because 18A is not external-customer friendly (likely the reason that the NVDA announcement is about ***co-developing*** chips) and 14A has to be proven before any big customer (AAPL, NVDA, AMD, AVGO, QCOM) bets their revenue streams on it. But certainly a number of smaller deals across both nodes would be big news. My options range from March 2026 through Dec 2027. Earlier this year those were relatively cheap; for example my 20-MAR-2026 15C was $6.76 (screenshot from ThinkOrSwim). https://preview.redd.it/r83ag6t8htsf1.jpeg?width=1714&format=pjpg&auto=webp&s=ee1e7aadf0a69b223c3be26b739f70f38519fe41 Believing there will be Foundry announcements (driven behind closed doors by the current administration) I even bought some recently as you can see above such as the 19-MAR-2027 35C @ $11.15. I like the long dated options because 1) they qualify as capital gains after a year and 2) after Delta reaches 1 they simply grow linearly with the stock price which I expect only to go up over the next 2 years (in the case of DEC 2027 calls). So an investment of \~$138k this year netted about $300k. (The other semi investment this year was TSM @ $175). So the next significant jump will depend on news about Foundry customers, but keep in mind it's trading way past fundamentals as Foundry will continue significant billion dollar losses probably for ***at least 4 quarters***, and the 14A node is a big question mark regarding PPA and yields. There is also a real possibility Foundry could be spun-off (yes I know there are clauses regarding that in the government funding but nothing that prevents it, or it could be (gasp!) nationalized) which will likely be positive for the stock price. Therefore I think it's still a good stock or (long-dated) call option investment as there is tremendous hype around Intel as well as the administration backing it. Just my two cents.
Im looking at $MSS, it showed promise but Im more cautious now
Thought on MSS.it was up 470 % before loosing all gains . Hoping for recovery
f. MSS, dumping, will have to add more
MSS - The company recently unveiled its quarterly results, showing a shift from net income to a net loss compared to the corresponding period from the previous year. Recent analyst recommendations have positioned Maison Solutions with a “Buy” rating, suggesting favorable future potential for stockholders. Been very active this week, worth a look.
Found MSS with a screener, looks like it's setting up for a big squeeze, what do you think? 20 mil volume and opened low, look at the graph, may squeeze.
Anything you guys have on your watch for AH today that are not stock mention this week here so far ? I became bag-holder on $MSS (luckily not a lot invested)
MSS secures $70M for digital asset Treasury It gained 470% yesterday but lost almost all gains by EOD. So hopefully it might gain some momentum today.
MSS - Announces Up to $70 Million private placement to Launch Worldcoin Digital Asset Treasury
Sold PSTV for profit, Holding DFLI. Might add MSS
DFLI and MSS seems to be good plays
Before the pump today MSS hit ~1.30 for 48 hours two weeks ago. The dip to sub 1$ seemed designed and saw resistance at .93-.95. I think it will see stability for a bit, and a buy under 1.40 is steal. Keep an eye on this one for sure, easily 2+ stable in the next few weeks.
Views on MSS. Secures $70 M for digital asset Treasury. Stock was up 470% but was back to original prices by EOD
MSS back on the move, went up 500% today then came back down to 0. Could be due for another run
Check out MSS. Here's your rubber band.
I feel like very few comments get removed on this sub, maybe if you posted it and did some DD and it got removed from that? Don't know, I just looked at your history and didn't see a MSS call out since today so.
I could be wrong, but I don’t think you called MSS? Unless you mean todsy, because I don’t see you calling it out since
Called NUAI at .40. Called MSS at .93 all within the same week. yet again, first one in the sub to drop tickers before the hype lol Do your own DD, next play im watching: KBLB